| Bioactivity | Cintirorgon sodium is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon sodium (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival[1][2]. |
| CAS | 2055538-47-9 |
| Formula | C27H22F6NNaO6S |
| Molar Mass | 625.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017. |
Cintirorgon sodium
CAS: 2055538-47-9 F: C27H22F6NNaO6S W: 625.51
Cintirorgon sodium is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon sodium (LYC-55716)
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.